Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advanced Cancer
Oral tazarotene is well tolerated when administered daily for 12 weeks
October 27th, 2003
Oral tazarotene is well tolerated when administered daily for 12 weeks in patients with advanced cancer. "Tazarotene is an acetylenic retinoid which is metabolized to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and RARgamma. The safety, toxicity and pharmacokinetics of oral tazarotene were determined over 12 weeks of treatment in 34 patients with advanced cancer," researchers in England report. "Commonly seen toxicities were mucocutaneous symptoms, musculoskeletal pain, and headache. Dose-limiting toxicities were hypercalcemia, hypertriglyceridemia, and musculoskeletal pain. The maximum tolerated dose of tazarotene...
Source: Health & Medicine Week (2003-10-27)
|
